Gene signature‐based prediction of triple‐negative breast cancer patient response to Neoadjuvant chemotherapy
Abstract Neoadjuvant chemotherapy is the current standard of care for large, advanced, and/or inoperable tumors, including triple‐negative breast cancer. Although the clinical benefits of neoadjuvant chemotherapy have been illustrated through numerous clinical trials, more than half of the patients...
Main Authors: | Yanding Zhao, Evelien Schaafsma, Chao Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3284 |
Similar Items
-
Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
by: Sarah Talamantes, et al.
Published: (2020-10-01) -
A Novel Three-Gene Score as a Predictive Biomarker for Pathologically Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
by: Masanori Oshi, et al.
Published: (2021-05-01) -
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
by: Olga O Gordeeva, et al.
Published: (2019-09-01) -
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
by: Qian Wang, et al.
Published: (2018-08-01) -
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
by: Victor Sarradin, et al.
Published: (2021-05-01)